Exhaled nitric oxide (FeNO): Bridging a knowledge gap in asthma diagnosis and treatment

TY - JOUR

T1 - Exhaled nitric oxide (FeNO)

T2 - Bridging a knowledge gap in asthma diagnosis and treatment

AU - Celis-Preciado, Carlos Andrés

AU - Lachapelle, Philippe

AU - Couillard, Simon

N1 - Funding Information: Carlos Andrés Celis-Preciado: reports speaker honoraria from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron. Philippe Lachapelle reports speaker honoraria from AstraZeneca, Sanofi-Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis outside of the submitted work; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron. Simon Couillard reports non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Fondation Québècoise en Santé Respiratoire, AstraZeneca, bioMérieux and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec's Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron and Valeo Pharma; he received consultancy fees for FirstThought, AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and will have stock options for Biometry Inc—a company developing a FeNO device (myBiometry). He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners. Supported by the Association Pulmonaire du Québec and the Fonds de Recherche du Québec. Funding Information: Carlos Andrés Celis‐Preciado: reports speaker honoraria from AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron. Philippe Lachapelle reports speaker honoraria from AstraZeneca, Sanofi‐Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis outside of the submitted work; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron. Simon Couillard reports non‐restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Fondation Québècoise en Santé Respiratoire, AstraZeneca, bioMérieux and Sanofi‐Genyme‐Regeneron; he is the holder of the Association Pulmonaire du Québec's Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi‐Regeneron and Valeo Pharma; he received consultancy fees for FirstThought, AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi‐Regeneron. He is an advisory board member and will have stock options for Biometry Inc—a company developing a FeNO device (myBiometry). He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners. Funding Information: Supported by the Association Pulmonaire du Québec and the Fonds de Recherche du Québec.

PY - 2023/8

Y1 - 2023/8

KW - FeNO

KW - asthma

KW - biomarkers

KW - exacerbations

UR - https://www.scopus.com/pages/publications/85167463026

U2 - 10.1111/cea.14374

DO - 10.1111/cea.14374

M3 - Editorial

AN - SCOPUS:85167463026

SN - 0954-7894

VL - 53

SP - 791

EP - 793

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 8

ER -